

2023 Expansion to Train New Addiction Providers Looking to Offer Patients Opioid Detox Without Fear

Speranza Therapeutics Provides Drug-Free Treatment Option to Rapidly Manage Opioid Withdrawal Symptoms

BOCA RATON, FL, USA, January 11, 2023 /EINPresswire.com/ -- In 2023, Speranza Therapeutics will expand its provider network with a regional focus. As the opioid epidemic tops record numbers annually, several states are experiencing extremely high rates of opioid addiction and overdose. The company has selected Indiana, Kentucky, and Ohio as the target region for its first quarter initiative to reach more providers.

Patients suffering from opioid use disorder (OUD) fear opioid withdrawal. This is the first, unavoidable step in recovery when they must stop opioid use and detox to enter the next level of treatment. Withdrawal is the number one reason patients avoid addiction treatment. Speranza Therapeutics has a revolutionary solution. <u>S.T. Genesis</u> is an FDA-cleared, noninvasive, drug-free medical device that reduces withdrawal symptoms within 60 minutes of



Speranza Therapeutics S.T. Genesis is an FDA-cleared medical device that helps to reduce opioid withdrawal symptoms




S.T. Genesis is compact and lightweight to allow patients to engage in their daily activities

application. It allows patients to comfortably transition through detox and enter the next steps of recovery.

"As a former clinician, I've witnessed the fear, pain, and anxiety of OUD patients going through

opioid withdrawal," explains Vaughn Bell, SVP of Growth Strategy at Speranza. "Our S.T. Genesis device offers detox without fear. Many patients start to feel relief within the first 20 minutes. As more providers become trained to apply the device in a specific area, we can offer more patients a better way to detox near their home and close to their support system within their community."

Helping a patient through opioid withdrawal is an emergent situation. When a patient decides it is time to quit opioids, they must have same-day access to the latest treatment options. By creating a regional concentration of trained providers with S.T. Genesis devices at their facilities, Speranza will provide faster, real-time access to its device for patients looking for a 20



After application of S.T. Genesis, the patient is monitored using the COWS score (Clinical Opiate Withdrawal Scale). Studies show a rapid reduction in withdrawal symptoms within 20 minutes and significant results within 60 minutes of application.

revolutionary way to deal with opioid withdrawal and start their recovery journey.

- S.T. Genesis can help providers and their facilities in several ways:
- Facilitating a smoother onboarding process for OUD patients by rapidly managing withdrawal symptoms at the beginning of treatment
- Minimizing stress on medical staff when a patient is calm and engages in a treatment plan immediately
- Reducing the number of patients leaving treatment prematurely against medical advice (AMA)

Speranza offers complimentary S.T. Genesis training to new providers with ongoing support during subsequent applications as needed. The device can be administered by any healthcare provider and may be used in an inpatient or outpatient setting. To date, Speranza Therapeutics has trained more than 300 providers. Interested providers should <u>contact Speranza</u> to learn more about the benefits and application of S.T. Genesis.

Accompanying its network expansion, Speranza is exploring programs with two major payers in the region. Speranza is confident that once new providers and patients experience the device's rapid results, it will help make S.T. Genesis a standard of care in opioid detox.

About Speranza Therapeutics

Founded in 2019, Speranza Therapeutics is more than a company that supplies a drug or device

to a patient or physician. We provide solutions as part of a medical protocol that help to produce positive outcomes for struggling patients.

Sal Rafanelli, RPh Speranza Therapeutics +1 844-477-3726 srafanelli@speranzatherapeutics.com Visit us on social media: LinkedIn Facebook YouTube

This press release can be viewed online at: https://www.einpresswire.com/article/610580195

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2024 Newsmatics Inc. All Right Reserved.